HMG20B

HMG20B (BRAF35/SMARCE1r) is a nuclear HMG-box and coiled-coil protein that functions as a core subunit of histone deacetylase/LSD1-CoREST repressor complexes to silence neuronal and differentiation gene programs (PMID:12032298, PMID:36171271). It was first isolated as a subunit of the six-protein BHC complex containing HDAC1/2, CoREST, BHC80, a PHD zinc-finger subunit and an MTA-like subunit, where it deacetylates histones and mediates REST-dependent repression of neuron-specific genes via the RE1/NRS element; a single point mutation in its HMG domain abrogates this repression (PMID:12032298). HMG20B associates with the nuclear matrix and binds DNA directly through its HMG domain (PMID:11997092). Genome-wide, it co-localizes with GFI1 and LSD1, and contacts LSD1 through its coiled-coil domain to stabilize LSD1 on chromatin at GFI1-binding sites, thereby enabling GFI1 repressor activity; depletion drives differentiation of AML and erythroid cells, identifying HMG20B as a repressor of hematopoietic differentiation acting through CoREST and downregulating Gfi1b (PMID:36171271, PMID:21606163). Its repressive function is regulated post-translationally: sumoylation is required for full target-gene repression, complex occupancy and antineurogenic activity, and is antagonized by heterodimerization with its paralogue iBraf, which displaces HMG20B from the LSD1-CoREST complex (PMID:22570500). Independently of its chromatin role, a C-terminal coiled-coil region (residues 173–317) binds the BRC5 repeat of BRCA2 and localizes HMG20B to cytokinetic structures, an activity required for completion of cytokinesis and separable from the BRC4-RAD51 recombination pathway; a cancer-associated Ala247Pro substitution disrupts both BRCA2 binding and cytokinesis in a trans-dominant manner (PMID:21399666, PMID:25486196). The E3 ligase MID1/TRIM18 modifies HMG20B with atypical K6/K27/K29-linked polyubiquitin chains that control its cytoplasmic stability and localization (PMID:28760657).

1. 2002 High

   Established HMG20B as a functional chromatin-repressor subunit rather than an isolated HMG protein, placing it within an HDAC-containing complex that silences neuronal genes.

   Evidence Biochemical isolation of the BHC complex, histone deacetylase assay, ChIP, and HMG-domain point mutation in human cells

   PMID:12032298

   Open questions at the time

   • Direct contribution of the HMG domain to chromatin engagement not structurally resolved
   • Whether HMG20B is obligate or accessory to deacetylase activity unclear
2. 2002 Medium

   Defined the biochemical activities of the protein — nuclear matrix association and intrinsic DNA binding — and its domain architecture (NLS, HMG box, coiled-coil).

   Evidence Subcellular fractionation, DNA-affinity chromatography, and EMSA on the human protein

   PMID:11997092

   Open questions at the time

   • No sequence-specific DNA target identified
   • Functional consequence of nuclear matrix association not tested
3. 2011 High

   Revealed an unexpected non-chromatin function: HMG20B is required for cytokinesis through a direct interaction with BRCA2 BRC repeats, distinct from BRCA2's recombination role.

   Evidence RNAi depletion, in vitro BRC-repeat binding assays, and BRC5 competition in cells

   PMID:21399666

   Open questions at the time

   • Molecular events downstream of HMG20B at the cleavage furrow unknown
   • How a nuclear repressor reaches cytokinetic structures unresolved
4. 2011 Medium

   Extended HMG20B's repressor role to hematopoiesis, showing it restrains erythroid differentiation predominantly by repressing target genes via CoREST.

   Evidence shRNA knockdown in mouse fetal liver cells and primary cells with microarray profiling and globin/Gfi1b readouts

   PMID:21606163

   Open questions at the time

   • Direct vs indirect regulation of Gfi1b not distinguished
   • Single lab, no complex reconstitution
5. 2012 High

   Identified sumoylation as a switch controlling HMG20B repressive output and complex occupancy, and defined iBraf as a heterodimeric antagonist.

   Evidence Sumoylation assays, Braf35/iBraf Co-IP, ChIP, and neuronal differentiation assays in P19 cells and chick neural tube

   PMID:22570500

   Open questions at the time

   • SUMO ligase/site stoichiometry not fully mapped
   • How sumoylation mechanistically enhances chromatin occupancy unclear
6. 2014 High

   Mapped the C-terminal coiled-coil region (173–317) as necessary and sufficient for BRCA2 binding and cytokinetic localization, and linked a cancer mutation to loss of this function.

   Evidence Domain truncation, cytokinesis rescue, Co-IP, localization imaging, and Ala247Pro mutation analysis

   PMID:25486196

   Open questions at the time

   • Structural basis of coiled-coil/BRC5 recognition not solved
   • Trans-dominant mechanism of the mutant not detailed
7. 2017 Medium

   Showed HMG20B is targeted by MID1/TRIM18 with atypical polyubiquitin chains that govern its cytoplasmic stability and localization, adding a second post-translational control layer.

   Evidence Co-IP, linkage-specific ubiquitination assays, MID1 depletion, fractionation and co-localization imaging

   PMID:28760657

   Open questions at the time

   • Functional consequence of ubiquitination for repressor or cytokinesis roles untested
   • Single lab, ubiquitination site not mapped
8. 2022 High

   Provided genome-wide mechanistic placement: HMG20B stabilizes LSD1 on chromatin at GFI1 sites via its coiled-coil domain to sustain GFI1 repression, and its loss drives leukemic differentiation.

   Evidence LSD1-complex mass spectrometry, HMG20B/GFI1/LSD1 ChIP-seq, depletion with differentiation readout, and domain-mapping Co-IP in AML cells

   PMID:36171271

   Open questions at the time

   • Whether HMG20B directly recruits or only stabilizes LSD1 unresolved
   • Generality across other CoREST target genes not established
9. 2022 Low

   Linked Dp71 to regulation of HMG20B nuclear distribution and downstream heterochromatin marks in neuronal cells.

   Evidence Overexpression of dominant-negative GFP-Dp71 mutants in neuronal cell lines with immunofluorescence and H3K9me2 staining

   PMID:36233175

   Open questions at the time

   • No direct biochemical interaction between Dp71 and HMG20B demonstrated
   • Localization-only readout in overexpression context
   • Mechanism connecting Dp71 to HMG20B unclear
10. 2024 Low

    Connected CPSF4-regulated alternative splicing of HMG20B to triple-negative breast cancer cell growth.

    Evidence RIP-seq/RNA-seq for splicing events, qRT-PCR validation, and HMG20B siRNA with proliferation/migration/invasion assays

    PMID:39731153

    Open questions at the time

    • Functional difference between the spliced isoforms not characterized
    • Single lab, limited molecular mechanism
    • Whether the chromatin or cytokinesis function drives the phenotype unknown

• How HMG20B's two functional arms — chromatin repression via LSD1-CoREST and BRCA2-dependent cytokinesis — are coordinated, and how its post-translational modifications partition it between these roles, remains unresolved.
• No structural model of the HMG20B coiled-coil bound to either LSD1 or BRCA2
• Interplay between sumoylation and MID1 ubiquitination not tested
• Whether the same molecules switch between nuclear and cytokinetic pools unknown